background
palivizumab
respiratori
synciti
viru
rsv
neutral
monoclon
antibodi
clinic
use
prevent
sever
rsv
infect
highrisk
infant
preterm
infant
infant
hemodynam
signific
heart
diseas
chronic
lung
diseas
palivizumab
act
block
fusion
step
viru
replic
mutant
resist
palivizumab
isol
vitro
also
children
rsv
infect
receiv
palivizumab
mutat
report
situat
fusion
protein
amino
acid
liaison
site
palivizumab
seem
mutat
liaison
site
confer
resist
palivizumab
gene
code
attach
glycoprotein
g
gene
rare
sequenc
aim
studi
analyz
complet
f
g
gene
sequenc
code
surfac
glycoprotein
rsv
isol
collect
patient
receiv
palivizumab
materi
method
rsv
isol
obtain
nasopharyng
swab
highrisk
infant
treat
palivizumab
univers
hospit
caen
octob
april
present
rsvbreakthrough
treatment
six
month
rsv
control
obtain
infant
receiv
palivizumab
viral
arn
extract
use
qiasymphoni
dsp
viruspathogen
mini
kit
group
type
hrsv
b
complet
use
real
time
rtpcr
amplif
sequenc
complet
f
g
gene
perform
use
onestep
rtpcr
kit
qiagen
hilden
germani
specif
primer
protocol
analysi
comparison
obtain
sequenc
refer
strain
control
sequenc
perform
bioedit
softwar
phylogenet
tree
construct
neighborjoin
method
mega
softwar
result
among
infant
treat
palivizumab
period
studi
present
rsv
infect
treatment
six
month
seven
rsva
rsvb
identifi
realtim
pcr
amplif
sequenc
f
g
gene
success
undertaken
rsva
analysi
phylogenet
tree
construct
use
rsva
detect
one
control
rsva
refer
sequenc
hrsva
isol
identifi
cluster
detect
cluster
genotyp
none
rsva
detect
analysi
complet
f
gene
align
hrsva
show
sever
mutat
liaison
site
palivizumab
found
one
mutat
liaison
site
mutat
previous
describ
mutat
confer
partial
resist
palivizumab
vitro
vivo
mutat
also
identifi
virus
collect
control
popul
conclus
studi
allow
us
character
mutat
rsv
case
palivizumab
treatment
failur
human
airway
epithelium
occupi
central
posit
pathogenesi
respiratori
virus
first
line
defens
microorgan
epithelia
cell
react
mucu
secret
mucociliari
clearanc
activ
releas
chemokin
cytokin
lipid
growth
factor
proteas
etc
viral
respiratori
infect
frequent
etiolog
acut
ill
worldwid
caus
mild
sever
diseas
common
cold
bronchiol
pneumonia
compar
studi
carri
infect
replic
frequent
human
respiratori
virus
use
standard
vitro
reconstitut
human
airway
epithelia
mucilair
tm
differenti
tissu
infect
parallel
clinic
relev
strain
rhinoviru
respiratori
enteroviru
influenza
viru
corona
viru
viru
replic
kinet
cell
tropism
impact
viru
tissu
integr
cilia
function
assess
develop
use
antivir
drug
one
prioriti
major
pharmaceut
compani
proofofconcept
drug
screen
efficaci
rupintruvir
oseltamivir
test
mucilair
tm
rupintruvir
effici
inhibit
replic
dose
time
depend
manner
inhibit
interestingli
oseltamivir
reduc
replic
restor
impair
barrier
function
monitor
transepitheli
electr
resist
ii
rupintivir
restor
mucociliari
clearanc
impair
ms
mock
ms
rupintrivir
treatment
nm
h
post
innocul
result
demonstr
mucilair
tm
robust
reliabl
relev
tool
antivir
drug
develop
main
econom
social
damag
result
infecti
diseas
throughout
world
caus
acut
respiratori
viral
infect
influenza
recent
year
epidem
process
character
cocircul
influenza
viru
subtyp
type
b
determin
etiolog
viral
infect
serolog
analysi
one
fundament
compon
monoclon
antibodi
mab
permit
dramat
increas
specif
sensit
diagnost
techniqu
detect
viral
antigen
immunolog
characterist
mab
produc
kazakhstan
isol
influenza
viru
studi
immunofluoresc
hai
microneutr
assay
immunofluoresc
test
reveal
mab
specif
homolog
relat
antigen
identifi
form
distinct
granular
fluoresc
conjug
dilut
found
mab
hai
assay
reveal
wide
rang
respons
high
titr
inhibit
hemagglutin
activ
homolog
relat
refer
kazakhstan
influenza
virus
react
heterolog
type
b
virus
microneutr
assay
mab
neutral
influenza
virus
react
influenza
virus
type
b
therebi
similar
spectra
mab
reactiv
virus
indic
presenc
antigen
determin
ha
composit
investig
virus
allow
recommend
result
mab
differenti
virus
season
type
b
strain
introduct
porcin
reproduct
respiratori
syndrom
viru
prrsv
rapidli
gain
import
one
econom
signific
diseas
swine
worldwid
prrsv
envelop
posit
singlestrand
rna
viru
divid
two
differ
genotyp
european
genotyp
type
north
american
genotyp
type
genom
prrsv
approxim
kb
length
contain
least
open
read
frame
orf
encod
one
variabl
region
prrsv
genom
often
use
examin
genet
divers
monitor
evolut
prrsv
studi
recent
isol
field
evalu
genet
variat
base
nucleotid
amino
acid
sequenc
materi
method
lung
serum
sampl
collect
pig
farm
nationwid
clinic
symptom
observ
total
rna
extract
serum
lung
use
rneasi
mini
kit
qiagen
accord
manufactur
protocol
obtain
sequenc
complet
revers
transcriptasepolymeras
chain
reaction
rtpcr
carri
use
one
step
rtpcr
kit
qiagen
prrsv
primer
set
deriv
sequenc
lv
strain
respect
multipl
sequenc
align
phylogenet
tree
carri
use
clc
main
workbench
mega
program
bootstrap
valu
calcul
replic
align
assess
confid
limit
branch
result
total
understand
genet
divers
characterist
prrsv
area
korea
analyz
open
read
frame
orf
sequenc
type
type
prrsv
result
show
type
circul
korea
pig
farm
region
rate
infect
preval
gyeongsangnamdo
provinc
korea
type
prrsv
korea
cluster
subtyp
subgroup
b
c
type
prrsv
classifi
lineag
new
korea
subgroup
b
recent
genet
type
prrsv
korea
becom
uniqu
region
characterist
gyeongsangnamdo
recent
genet
prrsv
asia
becom
divers
although
genet
type
prrsv
korea
uniqu
region
characterist
gyeongsangnamdo
genet
prrsv
asia
becom
divers
conclus
studi
prrsv
differ
geograph
area
perform
regularli
monitor
field
isol
would
provid
annual
genet
inform
prr
control
vaccin
select
andor
renew
